
22nd Century Group Market Cap | XXII
As of November 19, 2026 22nd Century Group has a market cap of $ 69.9 K
Capitalization is the market value of a company whose shares are traded on the stock exchange. It is calculated by multiplying the market price of a share by the total number of the company's shares. Capitalization indicates volatility, risk, and growth potential. This metric is often used for a quick assessment of a company’s investment profile.[1]
Capitalization is an important indicator for investors and analysts, as it helps determine the size and significance of a company in the stock market. Companies with large capitalization are considered more stable and reliable, as they have more resources and financial power to grow and survive in the market.
This metric can be divided into several categories: small (from 300 million to 2 billion dollars), medium (from 2 to 10 billion dollars), and large (over 10 billion dollars). Companies with different levels of capitalization have their own characteristics and risks, so investors usually take this indicator into account when making investment decisions.
Capitalization can also change over time depending on the share price and the number of shares in circulation. Therefore, it is a dynamic indicator that requires constant monitoring and analysis to make well-informed investment decisions.
Annual Market Cap 22nd Century Group
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 541 K | 1.64 K | 1.14 K | 11.4 M | 483 M | 347 M | 124 M | 290 M | 355 M | 73.5 M | 85.2 M | 70.2 M | 115 M | 26.2 M | 14.5 M | - | - |
Annual performance
Select metrics to display
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 483 M | 1.14 K | 133 M |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.
Market Cap of other stocks in the Biotechnology industry
| Issuer | Market Cap | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Seagen
SGEN
|
26.3 B | - | - | $ 42.2 B | ||
|
Baudax Bio
BXRX
|
779 K | - | 0.59 % | $ 63 K | ||
|
ChemoCentryx
CCXI
|
1.88 M | - | - | $ 3.74 B | ||
|
Avid Bioservices
CDMO
|
423 M | - | - | $ 789 M | ||
|
Zosano Pharma Corporation
ZSAN
|
52.7 M | - | 7.23 % | $ 2.72 M | ||
|
Spectrum Pharmaceuticals
SPPI
|
123 M | - | - | $ 189 M | ||
|
Alpine Immune Sciences
ALPN
|
269 M | - | - | $ 2.17 B | ||
|
RedHill Biopharma Ltd.
RDHL
|
24 B | $ 0.34 | -2.11 % | $ 4.19 B | ||
|
Berkeley Lights
BLI
|
117 M | - | -7.31 % | $ 87 M | ||
|
Stoke Therapeutics
STOK
|
2.01 B | $ 26.71 | 1.14 % | $ 1.58 B | ||
|
Kaleido Biosciences
KLDO
|
73.7 M | - | -3.69 % | $ 12.4 M | ||
|
VBI Vaccines
VBIV
|
9.65 M | - | -50.87 % | $ 1.09 M | ||
|
CTI BioPharma Corp.
CTIC
|
551 M | - | - | $ 1.2 B | ||
|
Decibel Therapeutics
DBTX
|
102 M | - | - | $ 123 M | ||
|
IVERIC bio
ISEE
|
2.97 B | - | - | $ 5.51 B | ||
|
ObsEva SA
OBSV
|
156 M | - | -15.52 % | $ 10.5 M | ||
|
Monopar Therapeutics
MNPR
|
401 M | $ 70.91 | -0.21 % | $ 526 M | ||
|
Myovant Sciences Ltd.
MYOV
|
1.4 B | - | -0.04 % | $ 2.62 B | ||
|
Poseida Therapeutics
PSTX
|
306 M | - | - | $ 857 M | ||
|
Y-mAbs Therapeutics
YMAB
|
216 M | - | - | $ 382 M | ||
|
Satsuma Pharmaceuticals
STSA
|
27.2 M | - | -0.9 % | $ 36.5 M | ||
|
Anavex Life Sciences Corp.
AVXL
|
291 M | $ 0.73 | -2.01 % | $ 62.3 M | ||
|
SpringWorks Therapeutics
SWTX
|
4.45 B | - | - | $ 3.48 B | ||
|
Metacrine
MTCR
|
13.5 M | - | - | $ 24.2 M | ||
|
Infinity Pharmaceuticals
INFI
|
17 M | - | -46.98 % | $ 3.57 M | ||
|
Ayala Pharmaceuticals
AYLA
|
7.72 M | - | - | $ 7.46 M | ||
|
Evelo Biosciences
EVLO
|
27 M | - | -14.46 % | $ 27.9 M | ||
|
Morphic Holding
MORF
|
1.52 B | - | - | $ 2.42 B | ||
|
Genocea Biosciences
GNCA
|
72.7 M | - | -15.0 % | $ 3.04 M | ||
|
Eiger BioPharmaceuticals
EIGR
|
3.11 M | - | -9.21 % | $ 2.55 M | ||
|
Amgen
AMGN
|
198 B | $ 444.49 | -2.93 % | $ 239 B | ||
|
IGM Biosciences
IGMS
|
84.7 M | - | - | $ 76.9 M | ||
|
Merrimack Pharmaceuticals
MACK
|
211 M | - | - | $ 216 M | ||
|
Rubius Therapeutics
RUBY
|
11.7 M | - | -33.55 % | $ 7.81 M | ||
|
Mirati Therapeutics
MRTX
|
2.56 B | - | - | $ 3.3 B | ||
|
InVivo Therapeutics Holdings Corp.
NVIV
|
3.15 M | - | -37.48 % | $ 476 K | ||
|
Bellicum Pharmaceuticals
BLCM
|
8.32 M | - | -9.72 % | $ 5.89 M | ||
|
vTv Therapeutics
VTVT
|
67.6 M | $ 16.51 | -4.51 % | $ 66.8 M | ||
|
Orchard Therapeutics plc
ORTX
|
672 M | - | 1.02 % | $ 90.8 M | ||
|
La Jolla Pharmaceutical Company
LJPC
|
127 M | - | - | $ 154 M | ||
|
Oyster Point Pharma
OYST
|
312 M | - | - | $ 300 M | ||
|
Intercept Pharmaceuticals
ICPT
|
706 M | - | - | $ 643 M | ||
|
Chinook Therapeutics
KDNY
|
1.39 B | - | - | $ 2.6 B | ||
|
Lumos Pharma
LUMO
|
24.6 M | - | - | $ 35.3 M | ||
|
MediWound Ltd.
MDWD
|
131 M | $ 13.61 | -0.51 % | $ 370 M | ||
|
Syros Pharmaceuticals
SYRS
|
165 M | - | -8.44 % | $ 3.4 M | ||
|
NanoViricides
NNVC
|
30.3 M | $ 1.19 | 2.59 % | $ 24 M | ||
|
Gamida Cell Ltd.
GMDA
|
353 M | - | -18.25 % | $ 5.04 M | ||
|
GT Biopharma
GTBP
|
2.59 M | $ 3.44 | 8.02 % | $ 19 M | ||
|
Bellerophon Therapeutics
BLPH
|
78.6 M | - | -74.18 % | $ 955 K |